帕金森病中的结构化药物评价:药剂师的观点,经验和需求 - - 一项定性研究
Nicol G M Oonk1,2, Lucille D A Dorresteijn3, Eline Te Braake4
1Department of Neurology, Medisch Spectrum Twente, PO Box 50000, Enschede 7500 KA, The Netherlands.
Therapeutic advances in drug safety
|May 2, 2024
概括
社区药剂师发现结构化药物评价 (SMR) 对帕金森病 (PD) 患者有价值,尽管面临时间和协作挑战,但提高了患者护理. 这些SMR强调了药剂师在管理复杂的PD药物治疗方案中的作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 患者护理 患者护理
- 定性研究是指质量研究.
背景情况:
- 结构化药物评价 (SMR) 是荷兰社区药剂师优化药物治疗的标准.
- 帕金森病 (PD) 患者有复杂的药物需求,可能从SMR中受益.
- 之前的研究发现,SMRs对PD患者的生活质量没有影响.
研究的目的:
- 从社区药剂师的角度分析帕金森病 (PD) 患者的SMR的过程和感知价值.
- 确定促进或阻碍PD患者执行SMR的因素.
主要方法:
- 一项定性研究,涉及面对面,半结构化的深入访谈与社区药剂师.
- 采访进行,直到数据和达到.
- 专题分析用于分析转录和编码的采访数据.
主要成果:
- 我们采访了13名药剂师.
- 在PD中,SMR被认为对患者接触,个性化护理和未来的结果有价值,尽管PD治疗主要是在二级护理中进行的.
- 关键的挑战包括时间限制,后勤问题以及与医疗专家的合作.
结论:
- 社区药剂师领导的SMR在PD患者的初级护理中提供了附加值,尽管耗时和物流具有挑战性.
- SMR强调药剂师在PD治疗和解决未来与药物有关的问题的关键作用.
- 建议加强多学科合作,以优化SMR执行和结果.
相关概念视频
Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Parkinson's Disease: Overview
537
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
537
Pharmacovigilance
829
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
829
Psychosis: Goals of Pharmacotherapy
124
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
124
Drug Administration and Therapy Phases: Overview
452
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
452


